Ex-vivo Confocal Imaging and Proteomic Profiling for Pediatric IBD
This study is looking at children and young adults (ages 2-21) with Inflammatory Bowel Disease (IBD). Researchers want to see if a special imaging technique called Confocal Laser Endomicroscopy (CLE) and other tests on tissue samples can help predict how well someone with IBD will respond to treatment. You would undergo standard procedures like an EGD (Esophagogastroduodenoscopy) and/or Ileocolonoscopy (IC) with CLE, where small tissue samples (biopsies) are taken. The goal is to understand how certain proteins in these biopsies relate to your treatment outcomes and to develop a way to predict who will respond best to different therapies. The study aims to enroll 40 participants, but its current status is unclear.
- Study design
- This is an interventional study planning to enroll 40 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would undergo an Esophagogastroduodenoscopy (EGD) and/or Ileocolonoscopy (IC) with Confocal Laser Endomicroscopy (CLE), which involves taking 3-4 mucosal biopsies.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, number of FITC tagged antibodies, is measured at Baseline. Further follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ex-vivo Confocal Imaging and Proteomic Profiling to Determine Treatment Response in Children With IBD
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Clifton Huang, MD · PRINCIPAL_INVESTIGATOR · Cook Children's Health Care System
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Number of FITC tagged antibodiesBaseline
Count of FITC tagged antibodies that maintain target specificity using fluorescence microplate reader. Used to establish baseline for fluorescent signal using FITC-tagged control antibody and control biopsy and IBD biopsy.